TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05801952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerobika* OPEP, PARI O-PEP (Flutter), PARI PEP® S System
Description: The 4-day physiotherapy program consists of performing bronchial drainage using one of the three devices: Aerobika\* OPEP Device (Trudell Medical International), Flutter - PARI O-PEP Device (PARI Respiratory Equipment, Inc.) and PEP - PARI PEP® S System (PARI Respiratory Equipment, Inc.).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerobika* OPEP, PARI O-PEP (Flutter), PARI PEP® S System
Description: The 4-day physiotherapy program consists of performing bronchial drainage using one of the three devices: Aerobika\* OPEP Device (Trudell Medical International), Flutter - PARI O-PEP Device (PARI Respiratory Equipment, Inc.) and PEP - PARI PEP® S System (PARI Respiratory Equipment, Inc.).
Study: NCT00283803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: luteinizing hormone-releasing hormone (LHRH) agonist
Description: Hormonal therapy to suppress testosterone as a standard treatment for Prostate Cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiandrogen
Description: Hormonal therapy used as lead in treatment with luteinizing hormone-releasing hormone (LHRH) agonist to prevent the initial rise in testosterone (testosterone flare) seen during the first dose of LHRH agonists.
Study: NCT04052789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BioHPP PEEK copings veneered with composite resin
Description: In the first visit, a Face-to-Face adherence session will be held in which the patient should be informed about the study steps and how to maintain oral hygiene measures. Further sessions will occur at the follow-up visits . Participant patients will be asked about any problems they are having. Patients will be recalled every two months for one year for follow up visits.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BioHPP PEEK copings veneered with composite resin
Description: In the first visit, a Face-to-Face adherence session will be held in which the patient should be informed about the study steps and how to maintain oral hygiene measures. Further sessions will occur at the follow-up visits . Participant patients will be asked about any problems they are having. Patients will be recalled every two months for one year for follow up visits.
Study: NCT03094091

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: News items with spin
Description: Interpretation of news items with spin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: News items without spin
Description: Interpretation of news items without spin
Study: NCT01126437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium 18 mcg
Description: HandiHaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium 1.25 mcg (2 actuations/day)
Description: soft mist inhaler 2 actuations=2 puffs/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium 2.5 mcg (2 actuations/day)
Description: soft mist inhaler (2 actuations=2 puffs/day)
Study: NCT06533501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Leucine Intakes
Description: Participants consume 8 hourly meals that contain the assigned test leucine intake. Each meal will provide one-twelfth of the participants' daily energy requirements as estimated by 1.5 x Resting Energy Expenditure (REE) and adequate protein at 1.0 g.kg.d, to maintain a metabolic steady state. The meals are in the form of a crystalline amino acid protein shake, and protein-free cookies.
Study: NCT02851797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: givinostat
Description: The oral suspension of givinostat (10 mg/mL) was to be dosed in fed condition as described below:~Givinostat or placebo starting dose~* \> or =10 and \< 12.5 kg of weight: 13.3 mg bid = 1.3 ml oral suspension bid~* \> or =12.5 and \< 20 kg: 16.7 mg bid =1.7 ml oral suspension bid~* \> or = 20 and \< 25 kg: 20 mg bid = 2.0 ml oral suspension bid~* \> or = 25 and \< 30 kg: 23.3 mg bid = 2.3 ml oral suspension bid~* \> or = 30 and \< 40 kg: 26.7 mg bid = 2.7 ml oral suspension bid~* \> or = 40 and \< 50 kg: 33.3 mg bid = 3.3 ml oral suspension bid~* \> or = 50 and \< 60 kg: 36.7 mg bid = 3.7 ml oral suspension bid~* \> or = 60 and \< 70 kg: 40 mg bid = 4 ml oral suspension bid~* \> or = 70 kg: 46.7 mg bid = 4.7 ml oral suspension bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The oral suspension of placebo, manufactured to mimic givinostat, was to be dosed in fed condition as described for givinostat.
Study: NCT02820246

Intervention type: OTHER
Intervention: nutrition
Description: type and amount of food eaten or type of oral nutritional supplements as well as enteral or parenteral nutrition
Study: NCT01744808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EB-1020 IR
Description: Immediate release

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EB-1020 SR1
Description: sustained release
Study: NCT04229992

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium glycinate
Description: Oral administration of magnesium glycinate daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium glycinate
Description: Oral administration of magnesium glycinate daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of identical-appearing placebo daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of identical-appearing placebo daily for 12 weeks
Study: NCT01731392

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk with Bifidobacteria
Description: A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk with non replicating lactobacilli
Description: A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
Study: NCT03388879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taylor Spatial Frame
Description: Circular external fixator
Study: NCT05801952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerobika* OPEP, PARI O-PEP (Flutter), PARI PEP® S System
Description: The 4-day physiotherapy program consists of performing bronchial drainage using one of the three devices: Aerobika\* OPEP Device (Trudell Medical International), Flutter - PARI O-PEP Device (PARI Respiratory Equipment, Inc.) and PEP - PARI PEP® S System (PARI Respiratory Equipment, Inc.).
Study: NCT04913948

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02400853

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard cranial echography
Description: Standard cranial echography will be done at day 5 day 7 post-birth looking for radiological finding of intraventricular hemorrhage

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard cranial echography
Description: Standard cranial echography will be done at day 5 day 7 post-birth looking for radiological finding of intraventricular hemorrhage
Study: NCT01744808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EB-1020 SR2
Description: Sustained release

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EB-1020 SR3
Description: Sustained release

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo formulation
Study: NCT00853580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin ™
Description: Lovastatin starting at 20mg for 2 weeks, increasing to 40mg for 14 weeks. Total duration of trial is 16 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Starting at 20mg for 2 weeks, then increasing to 40mg for 14 additional weeks for a total duration of treatment of 16 weeks.
Study: NCT01767467

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccine (GSK 1437173A)
Description: 2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.
Study: NCT01384890

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: VMAT with CBCT
Description: volumetric modulated arc therapy (VMAT) with cone-beam computed tomography (CBCT) position verification

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: VMAT with kV-ray
Description: Volumetric modulated arc therapy (VMAT) with kV-ray position verification
Study: NCT03177590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recordings of facial and vocal emotional productions
Description: Children are asked to perform three tasks:~1. an emotional production on imitation (the child with autism or TED will imitate the emotion expressed by an animated avatar)~2. an emotional production by mime of the emotion on command (oral and written) without visualizing the model of imitation~3. Emotional production in context: the child with autism or EFD will describe images forming the story of Frog and as it is read, will produce the appropriate facial and vocal emotions in the context.
Study: NCT04694066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong
Description: Qigong Baduanjin, comprising eight standardized movements, will be adopted in the study. It is practiced as a combination of body movements, breath control, and mindful meditation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Light flexibility exercise
Description: The supervised sessions will include seated and standing stretches that target upper (neck, arms, upper back, shoulders, and chest) and lower body (quadriceps, hamstrings, calves, and hips), as well as trunk rotations.
Study: NCT03462485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Golf
Description: Eight weeks of twice-daily golf training
Study: NCT03504904

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-Delivered ACT and CFT
Description: An 8-week internet-based intervention focused on acceptance and compassion. Psychological intervention based on Acceptance and commitment therapy and compassion focused therapy
Study: NCT02400853

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord blood analysis
Description: Cord blood will be collected during deliverance and analysed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cord blood analysis
Description: Cord blood will be collected during deliverance and analysed
Study: NCT04141826

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolysed whey
Description: 500 mL solution of 25 gram hydrolysed whey per day during 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intact whey
Description: 500 mL solution of 25 gram intact whey per day during 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Caseinate
Description: 500 mL solution of 25 gram casein ate per day during 4 weeks
Study: NCT02330653

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant (FMT)
Description: The study intervention consists of frozen, bottled or encapsulated fecal microbiota preparations that have been screened and prepared to a uniform and rigorous standard by OpenBiome. FMT is performed by patients receiving a retention enema and swallowing capsules, introducing stool from a healthy donor into their intestinal tract.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administration will consist of both a placebo retention enema and placebo capsules.
Study: NCT01358669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: 60mg denosumab by injection as a single dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by injection as a single dose
Study: NCT01034306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101
Description: orally q12h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: orally q12 hours
Study: NCT02714075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ferric Pyrophosphate and Zinc Oxide
Description: Extruded rice fortified with Ferric Pyrophosphate, Zinc Oxide (ZnO) and micronutrients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ferric Pyrophosphate and Zinc Sulphate
Description: Extruded rice fortified with Ferric Pyrophosphate, Zinc Sulphate (ZnSO4) and micronutrients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ferric Pyrophosphate, ZnO, Citric Acid and Trisodium Citrate
Description: Extruded rice fortified with Ferric Pyrophosphate, Zinc Oxide (ZnO), Citric Acid (CA) and Trisodium Citrate (TSC) and micronutrients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ferric Pyrophosphate, ZnSO4, CA/TSC
Description: Extruded rice fortified with Ferric Pyrophosphate, ZnSO4, CA/TSC and micronutrients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ferric Pyrophosphate, ZnO, CA, EDTA
Description: Extruded rice fortified with Ferric Pyrophosphate, ZnO, CA, EDTA and micronutrients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ferrous Sulphate
Description: Extruded rice fortified with micronutrients, Ferrous Sulphate solution will be added at consumption
Study: NCT06120218

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emergent Stenting
Description: Emergent Stenting in acute ischemic stroke caused by tandem occlusions
Study: NCT00842153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate foam
Description: Topical Clobetasol propionate foam
Study: NCT03618758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intraperitoneal application of Paclitaxel Phase 1: Dose determination of Paclitaxel (Recommended Dose) Starting from 40mg/m² upto 100mg/m² maximum~Phase 2: Intraperitoneal Paclitaxel with recommended dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 regimen
Description: Systemic mFOLFOX6: 5-FU(2400mg/m²), Oxaliplatin(100mg/m²), Leucovorin(100mg/m²)
Study: NCT01988402

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: allopurinol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sugar pill)
Study: NCT03781349

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MENS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Study: NCT01462799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PBL in patient education
Description: The experiment group will enter a PBL patient education that is characterised by autonomous learning. The patients work together in small groups. Focus is on lifestyle changes. Starting point of learning is the patient's individual life style goals. Thirteen meetings during 1 year for 2 hours; weekly for the first month, every second week next two months and the last meetings 16, 20 and 26, 39 and 52 weeks after start. The programme shall be completed 1 year after start. The patients work with starting triggers such as pictures, texts, or concrete materials. Nurses work as tutors (after completion of a tutorial education) during the meetings using a problem based model to support patients formulate issues and goals to work with during the year. When the patients do not solve question the possibility of inviting e.g. a GP, dietician, pharmacist or physiotherapist is possible.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mailed patient information
Description: During the study year patients in this control group will receive mailed patient information about life style changes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mailed patient information
Description: During the study year patients in this control group will receive mailed patient information about life style changes.
Study: NCT03388879

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intramedullary nail
Description: Antegrade intramedullary nail
Study: NCT00842153

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle foam
Description: Vehicle foam does not include the active drug.
Study: NCT04295681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMH-MAP
Description: Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study: NCT03001206

Intervention type: DEVICE
Intervention: Master Caution System
Description: The purpose of this study is to evaluate the effectiveness and usability of the Master Caution System for 12 leads continuous monitoring of ECG signal in the ICCU.~The purpose of the study is to evaluate the effectiveness and usability of using Master Caution 12 leads Garment for stress test.~The purpose of the study is to reassess the adequate size of the Master Caution Garment (MCG).

Intervention type: DEVICE
Intervention: Master Caution System
Description: The purpose of this study is to evaluate the effectiveness and usability of the Master Caution System for 12 leads continuous monitoring of ECG signal in the ICCU.~The purpose of the study is to evaluate the effectiveness and usability of using Master Caution 12 leads Garment for stress test.~The purpose of the study is to reassess the adequate size of the Master Caution Garment (MCG).
Study: NCT01749319

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral baclofen
Description: Each subject will receive one dose of oral baclofen and one dose of intravenous baclofen on different study days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervenous baclofen
Study: NCT02108704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Helicobacter pylori eradication therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01351376

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low Level Laser Therapy
Description: Placebo LLL combined with CDT

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Level Laser
Description: Active LLL combined with CDT
Study: NCT01170208

Intervention type: DEVICE
Group type: OTHER
Intervention: insulin dose software
Description: The rationale to conduct this study is that Hygieia hypothesizes the software will effectively and safely optimize glucose control in insulin-requiring patients with type-1 and type-2 diabetes. The software was designed to provide safe insulin dosage recommendations.

Intervention type: DEVICE
Group type: OTHER
Intervention: insulin dose software
Description: The rationale to conduct this study is that Hygieia hypothesizes the software will effectively and safely optimize glucose control in insulin-requiring patients with type-1 and type-2 diabetes. The software was designed to provide safe insulin dosage recommendations.

Intervention type: DEVICE
Group type: OTHER
Intervention: insulin dose software
Description: The rationale to conduct this study is that Hygieia hypothesizes the software will effectively and safely optimize glucose control in insulin-requiring patients with type-1 and type-2 diabetes. The software was designed to provide safe insulin dosage recommendations.
Study: NCT02491489

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glenohumeral mobilization
Description: Participants will then be placed supine on a standard plinth. The investigators will then proceed to provide a mobilizing force to the participant's glenohumeral joints. Each of two investigators will, in sequence perform a 15 second longitudinal distraction, followed by a 15 second posteriorly directed glenohumeral glide with the shoulder placed in the open pack resting position (\~50 degrees abduction, slight horizontal adduction, external rotation).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glenohumeral mobilization
Description: Participants will then be placed supine on a standard plinth. The investigators will then proceed to provide a mobilizing force to the participant's glenohumeral joints. Each of two investigators will, in sequence perform a 15 second longitudinal distraction, followed by a 15 second posteriorly directed glenohumeral glide with the shoulder placed in the open pack resting position (\~50 degrees abduction, slight horizontal adduction, external rotation).
Study: NCT03072888

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TENS
Description: Transcutaneous Electrical Nerve Stimulation will be apply

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: Transcutaneous Electrical Nerve Stimulation will be apply
Study: NCT03937765

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP harvest and preparation
Description: The PRP harvest and preparation will be done in the operating room with the help of the hospital blood bank. The skin graft surgery will be completed by Dr. Jason Lowe and/or one of the Orthopaedic Surgery residents. Follow up will also be completed by Dr. Lowe or one of the residents. Data analysis will be done by Drs. Lowe and Manoharan.~Each patient that will be undergoing a skin graft surgery will be randomized into either the PRP (intervention) group or the control group. Follow up and dressing changes will be the same for both groups. Each group will be prescribed a multi-modal pain regimen to reduce narcotic usage.
Study: NCT02955563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSDM Web-Based Tool Intervention
Description: The web and tablet-based tool is designed to help family members become familiar with ICU environment, routines, and clinicians, prepare for family meetings, and learn how to make values-based decisions for their loved one. The tool contains short videos, interactive exercises, and links to other resources. Family members work through the tool shortly after admission to the ICU, before each family meeting, and any other time they wish to during the ICU admission.
Study: NCT02785159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-118 Lotion
Description: Lotion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazorac Cream
Description: Cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-118 Vehicle Lotion
Description: Lotion
Study: NCT04521686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3410738
Description: Oral LY3410738
Study: NCT02785159

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-118 Vehicle Cream
Description: Cream